You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨信達生物(01801.HK)高開3.43% 與MD Anderson共同開發PD-1抑制劑達伯舒
格隆匯 05-19 09:25
格隆匯5月19日丨信達生物(01801.HK)高開3.43%,報46.7港元,總市值627億港元。信達生物今日早間發佈公告,公司與美國德州大學MD Anderson癌症中心(“MD Anderson”)達成了一項戰略合作協議,以在美國聯合開發創新抗PD-1單克隆抗體達伯舒® (信迪利單抗注射液)用於治療多種罕見癌症。MD Anderson在開展臨牀研究甚至其他中心不常見的罕見癌症臨牀研究方面擁有獨特經驗,使得這項聯合開發成為可能。這些研究將使公司有機會獲得美國食品藥品監督管理局批准信迪利單抗的多個罕見癌症適應症。此外,公司也在獨立負責信迪利單抗更大癌症適應症的上市申請工作。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account